Navigation Links
Silence Therapeutics Additional Listing
Date:12/20/2011

LONDON, December 20, 2011 /PRNewswire/ --

Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") a leading global RNA interference (RNAi) therapeutics company, today announces that application has been sought for 530,000 new ordinary shares of 1 pence each ("Ordinary Shares") to be admitted to trading on AIM. The new Ordinary Shares are being issued in accordance with a contractual agreement with Dr. Philip Haworth, former Chief Executive Officer of Silence.

It is expected that dealings in the new Ordinary Shares, which will rank pari passu in all respects with the existing issued share capital of the Company, will commence on 21 December 2011.

Notes for editors

About Silence Therapeutics plc (http://www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases. Silence offers one of the most comprehensive short interfering RNA (siRNA) therapeutic platforms available today based on a strong intellectual property portfolio and large clinical safety database. Silence's clinical siRNA product pipeline is one of the broadest in the industry.

The Company possesses multiple proprietary siRNA delivery technology platforms including AtuPLEX™, DACC and DBTC. AtuPLEX enables the broad functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. The DACC delivery system allows functional delivery of siRNA molecules selectively to the lung endo-thelium with a long duration of target mRNA and protein knock-down. The DBTC delivery system enables functional deli
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
2. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
3. Silence Therapeutics Appoints New Vice President of Research
4. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
5. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
6. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
7. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
8. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
9. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
10. Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
11. Silence Therapeutics Provides Corporate and Development Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... (PRWEB) June 18, 2013 (PRWEB) June 18, 2013 ... time and attendance system in North America, has ... shares employee data and payroll records between ExakTime’s ... Plus automates ExakTime software setup and keeps ... imports employee data from a business’ current payroll ...
(Date:6/18/2013)... Phoenix, AZ (PRWEB) June 18, 2013 ... the 2013 Innovation Challenge Winner out of hundreds of ... in its spring Arizona Innovation Challenge . The ... the country for a technology commercialization challenge, granting a ... world’s most promising technology ventures. Nasseo’s state of the ...
(Date:6/18/2013)... 2013  AMRI (NASDAQ: AMRI ) ... , site has received approval to expand ... to handle Schedule 2 and 2N controlled substances. ... Burlington,s physical security and quality ... (Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO ) With ...
(Date:6/18/2013)... Research and Markets ... of the report " DNA Sequencing - ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... human genome variations, development of sequencing technologies, ... sequencers are described as well as companies ...
Breaking Biology Technology:ExakTime Introduces AccountLinx Plus 2Nasseo Named 2013 Innovation Challenge Winner by Arizona Commerce Authority 2AMRI Burlington Receives DEA Approval to Handle Controlled Substances 2DNA Sequencing: Technologies, Markets and Companies - 2013 Report 2
... has been so much media attention focused on the ... finally shedding some light on the issue. Whatever the ... America to cheaper labor. The effects of this are ... It doesnt matter what you are making, whether you ...
... Among the reasons North Carolina Sen. John Edwards polled ... thinks the North American Free Trade Agreement has been a ... voters who are eager to blame the states economic troubles ... really not that short-sighted. Free trade is a part of ...
... Wis.- Gundersen Lutheran Health System is reducing surgery delays ... management of its surgical instruments and trays by using ... Minn.- based Lawson Software. , ,Gundersen Lutheran operates ... of the nation's largest group medical practices, community clinics, ...
Cached Biology Technology:Offshore outsourcing affects American workers 2Offshore outsourcing affects American workers 3A Vote Against Free Trade is a Vote Against Wisconsins Long-Term Interests 2Gunderson Lutheran Implements Instrument Management Systems 2
(Date:6/17/2013)... and algae, is a common component of sugar-free gum ... medical field it,s approved by the FDA as ... during surgery as a substance that opens the blood/brain ... Now Profs. Ehud Gazit and Daniel Segal of Tel ... the Sagol School of Neuroscience, along with their colleague ...
(Date:6/17/2013)... The AGA Research Foundation and Horizon Pharma further establish ... with the 2013 AGA-Horizon Pharma Fellow Abstract Prizes and ... its third year, this competition continues to grow in ... careers in basic and clinical research," said Nicholas F. ... "We are extremely proud of all that these fellows ...
(Date:6/17/2013)... Amphibian populations are declining worldwide and a major cause ... bullfrogs, but a two-year study shows they can also ... are a tolerant carrier host that just spreads the ... in controlled experimental conditions, they found at least one ... called Bd or a chytrid fungus, can be fatal ...
Breaking Biology News(10 mins):Artificial sweetener a potential treatment for Parkinson's disease 2Horizon Pharma Abstract Prizes recognize promising fellows and students 2Bullfrogs may help spread deadly amphibian fungus, but also die from it 2
... more foreign children in the classroom, and many of them ... A study by the University of Gerona has assessed the ... that they take at least six years to acquire the ... system that has proven successful in other countries as a ...
... at the University of Leeds have come a step closer ... Their findings, published in the International Journal of ... developed to tackle other cancers should be considered as a ... as tamoxifen, that target a protein responsible for tumour growth, ...
... at The University of Texas Health Science Center at ... study the spread of E. coli , a ... Jennifer Juarez received fellowships from the American Society for ... The ASM fellowship supports professional development and the NIH ...
Cached Biology News:Foreign children take at least 6 years to learn the language used in school 2Foreign children take at least 6 years to learn the language used in school 3Another step toward resisting breast cancer 2UTHealth student earns fellowships to research major source of bacterial infections 2
... Ultrasonic Nebulizers are available in two product models ... these two models is that the 6000AT+ includes ... a drier aerosol for improved detection limits and ... for a range of elements by 10-40 times. ...
...
... For potent inhibition of RNase A-type ribonucleases ... protein of nonhuman origin that binds noncovalently ... RNase A, B, and C). It does ... U1, U2, or CL3. QIAGEN RNase Inhibitor ...
...
Biology Products: